山东金城医药集团股份有限公司全资子公司北京金城泰尔制药有限公司（以 下简称"金城泰尔"）及控股子公司广东金城金素制药有限公司（以下简称"金 城金素"）参与了国家组织药品集中采购和使用联合采购办公室（以下简称"联 合采购办公室"）组织的第十一批全国药品集中采购的投标工作，金城泰尔瑞巴 派特片和金城金素注射用头孢唑肟钠拟中选本次集中采购，现将相关情况公告如 下： 证券代码：300233 证券简称：金城医药 公告编号：2025-073 山东金城医药集团股份有限公司 关于子公司参与全国药品集中采购拟中选的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 注：1、上述品种的具体中选情况以联合采购办公室发布的最终数据为准。 | 产品 | 注册 | 适应症或功能主治 | 申报品规 | 拟中选价格 | 拟中选 | | --- | --- | --- | --- | --- | --- | | 名称 | 分类 | | | | 区域 | | 瑞 巴 派 特 | 化学药品 | 主要用于改善胃溃疡、急性 胃炎、慢性胃炎急性加重期 | 0.1g*24 片/盒 | 4.68 元/盒 ...

Core Viewpoint - Jincheng Pharmaceutical (300233) reported a significant decline in financial performance for Q3 2025, with net profit dropping by 79.1% year-on-year, indicating potential challenges in revenue generation and cost management [1]. Financial Performance Summary - Total revenue for Q3 2025 was 1.932 billion yuan, a decrease of 23.19% compared to 2.515 billion yuan in Q3 2024 [1]. - The net profit attributable to shareholders for Q3 2025 was 31.577 million yuan, down 79.1% from 151 million yuan in Q3 2024 [1]. - The gross profit margin decreased to 36.23%, down 9.73% year-on-year, while the net profit margin fell to 1.74%, a decline of 73.02% [1]. - Total expenses (selling, administrative, and financial) amounted to 520 million yuan, accounting for 26.93% of revenue, a slight increase of 0.28% year-on-year [1]. - Earnings per share dropped to 0.08 yuan, a decrease of 80% from 0.4 yuan in the previous year [1]. Business Strategy and Developments - The company is focusing on the women's health sector, enhancing its product pipeline and leveraging upstream raw material advantages to prioritize "chain products" [3]. - Jincheng Pharmaceutical is actively pursuing international collaborations, including a licensing agreement with UK-based Theramex for hormone replacement therapy products in China [5]. - The subsidiary Jincheng Tail is expanding its sales channels and product offerings in the women's health technology field, indicating a strategic push towards growth in this area [5][6]. Operational Insights - The company's return on invested capital (ROIC) was reported at 4.91%, indicating weak capital returns, with a historical median ROIC of 5.75% over the past decade [4]. - The cash flow situation is concerning, with cash and cash equivalents to current liabilities ratio at 98.49%, and accounts receivable reaching 213.38% of profit, suggesting potential liquidity issues [4].

Core Viewpoint - Jin Cheng Pharmaceutical reported a revenue of 1.932 billion and a net profit of 31.577 million for the first three quarters of 2025, highlighting short-term performance pressure due to industry conditions but showcasing improvements in financial structure, core business breakthroughs, and increased institutional recognition, indicating the long-term value of strategic layout is gradually emerging [1][2]. Financial Performance - The company achieved a revenue of 1.932 billion and a net profit of 31.577 million in the first three quarters of 2025 [1]. - The asset-liability ratio decreased to 27.69% by the end of the third quarter, down from 31.63% at the end of 2024, marking a significant decline of 3.94 percentage points [1]. Shareholder Structure - The investment value of the company has been highly recognized by professional institutions, with new entries from national social security funds in the top ten circulating shareholders, indicating market confidence in the company's long-term development logic [1]. Strategic Business Development - The company has focused on high-end pharmaceutical chemicals, synthetic biology, women's health technology, and high-end anti-infection fields, forming a strategic development layout supported by five major areas [2]. - Jin Cheng Pharmaceutical has actively participated in various provincial and national centralized procurement efforts, leading to significant sales growth in its biological and specialty raw materials segment [2]. Research and Development Achievements - The company has accelerated the transformation of R&D results, with multiple product registrations and certifications both domestically and internationally, including the approval of various formulations and raw materials [3]. - Jin Cheng Pharmaceutical plans to continue focusing on the five major areas of "pharmaceutical chemicals, synthetic biology, women's health technology, high-end anti-infection, and new tobacco," aiming to enhance business boundaries and increase industry added value [3].

Core Insights - The article highlights the recent movements of social security funds in the stock market, revealing that 43 new stocks were added to their portfolio in the third quarter [1] - A total of 1,315 companies have released their third-quarter reports, with social security funds appearing in 156 stocks, indicating significant institutional activity [1] Summary by Category New Investments - Social security funds initiated positions in 43 new stocks during the third quarter [1] - Among the new stocks, the highest holdings were in Jin Cheng Pharmaceutical (11.89 million shares), Kesi Da (10.52 million shares), and Huazheng New Materials (3.70 million shares) [1] - The stock with the highest proportion held by social security funds is Jin Cheng Pharmaceutical, accounting for 3.20% of its circulating shares [2] Performance Metrics - In terms of performance, 30 of the newly invested stocks reported year-on-year net profit growth, with Huazheng New Materials showing the highest increase of 1,042.19% [2] - The average increase of the newly invested stocks since October is 0.96%, which underperformed compared to the Shanghai Composite Index [2] - The best-performing stock among the new investments is Beifang Changlong, with a cumulative increase of 28.05% [2] Holdings Overview - A detailed list of stocks newly invested by social security funds includes Jin Cheng Pharmaceutical, Yi Yi Co., Huazheng New Materials, and others, with varying levels of holdings and industry classifications [2][3] - Notable holdings include Jiangsu Jinzu (45.65 million shares) and Fangzheng Technology (30.13 million shares), indicating a diverse investment strategy across different sectors [3]

Group 1 - The core viewpoint of the news is that Jincheng Pharmaceutical (300233.SZ) has seen an increase in institutional investor holdings, with a total of 1.13 billion shares held by 9 institutions, representing 29.44% of the total share capital, which is an increase of 4.77 percentage points compared to the previous quarter [1] Group 2 - In the public fund sector, 2 new public funds disclosed their holdings in Jincheng Pharmaceutical this quarter, including the Fuguo Precision Medical Flexible Allocation Mixed Fund and the Xingquan Light Asset Mixed Fund (LOF) [1] - A total of 14 public funds were not disclosed this quarter, including major funds such as Dachen Jingheng Mixed A and Dachen Zhuoxiang One-Year Holding Mixed A [1] Group 3 - For social security funds, 2 new social security funds disclosed their holdings in Jincheng Pharmaceutical, namely the National Social Security Fund 502 Portfolio and the National Social Security Fund 601 Portfolio [2] - In terms of foreign investment, one foreign fund, Hong Kong Central Clearing Limited, reduced its holdings by 0.56% compared to the previous quarter [2]

Group 1 - Shuyou Shen plans to raise no more than 1.253 billion yuan through a private placement to support innovative drug research and supplement working capital [1] - The issuance will involve no more than 143 million shares, with the price set at no less than 80% of the average trading price over the previous 20 trading days [1] Group 2 - WuXi AppTec reported a 84.84% year-on-year increase in net profit for the first three quarters, reaching 12.076 billion yuan, driven by a focus on CRDMO business and gains from selling shares in WuXi XDC Cayman Inc. [2] - The company achieved a revenue of 32.857 billion yuan, marking an 18.61% year-on-year growth [2] Group 3 - Wanfu Bio's net profit for the first three quarters decreased by nearly 70%, with a revenue of 1.69 billion yuan, down 22.52% year-on-year [3] - The third quarter revenue was 445 million yuan, a decline of 26.66% [3] Group 4 - Jincheng Pharmaceutical reported a 79.1% year-on-year decrease in net profit for the first three quarters, totaling 31.58 million yuan, with a revenue of 1.932 billion yuan, down 23.19% [4] - The third quarter revenue was 572 million yuan, a decline of 24.44% [4] Group 5 - WuXi AppTec plans to transfer 100% equity of two subsidiaries for a base price of 2.8 billion yuan, aiming to reinvest the funds into core business areas [5] - The sale of non-core assets is expected to enhance the company's competitiveness and potentially provide a short-term boost to stock prices [5]

Group 1 - Jincheng Pharmaceutical (SZ 300233) announced on October 26 that its 17th meeting of the 6th board of directors was held on October 23, 2025, to review proposals including the revision and establishment of certain corporate governance systems [1] - For the year 2024, Jincheng Pharmaceutical's revenue composition is 100% from the pharmaceutical manufacturing industry [1] - As of the report date, Jincheng Pharmaceutical has a market capitalization of 6.6 billion yuan [1]

山东金城医药集团股份有限公司 信息披露管理制度 山东金城医药集团股份有限公司 信息披露管理制度 第一章 总 则 第一条 为加强山东金城医药集团股份有限公司（以下简称"公司"或"本公 司"）信息披露工作管理，规范信息披露行为，维护公司、投资者及其他利益相 关者的合法权益，根据《中华人民共和国公司法》《中华人民共和国证券法》（以 下简称"《证券法》"）《上市公司信息披露管理办法》《深圳证券交易所创业 板股票上市规则》《深圳证券交易所创业板上市公司自律监管指引第 2 号—创业 板上市公司规范运作》《深圳证券交易所上市公司自律监管指引第 5 号—信息披 露事务管理》以及《山东金城医药集团股份有限公司章程》（以下简称"《公司 章程》"）等有关规定，并结合公司实际情况，制定本制度。 第二条 本制度所称"信息"是指根据法律法规和深圳证券交易所（以下简称 "深交所"）相关规则应当披露的，可能对公司股票及其衍生品种交易价格或投 资决策产生较大影响的信息以及证券监管部门要求披露的信息，或者公司主动披 露的信息。 本制度所称的"披露"是指公司及相关信息披露义务人在规定的时间内、在 规定的媒体上、以规定的方式向社会公布上述定义的信息 ...

山东金城医药集团股份有限公司 总裁工作细则 山东金城医药集团股份有限公司 总裁工作细则 第一章 总则 第一条 为完善山东金城医药集团股份有限公司（以下简称"公司"）法人治 理结构，规范经营层行为，确保公司生产经营管理工作的顺利进行，根据《中华 人民共和国公司法》《中华人民共和国证券法》《上市公司治理准则》《深圳证 券交易所创业板股票上市规则》《深圳证券交易所上市公司自律监管指引第 2 号 —创业板上市公司规范运作》等相关有关法律、行政法规、规范性文件及《山东 金城医药集团股份有限公司章程》（以下简称"《公司章程》"）的规定，制定 本细则。 第二条 本细则所称总裁及高级管理人员是指公司总裁、副总裁、财务负责人 和董事会秘书。 第二章 总裁的聘任和解聘 第三条 公司设总裁一名，由董事长提名，董事会聘任或解聘。公司设副总裁 若干名，由董事会根据总裁的推荐予以聘任或解聘。 董事可受聘兼任总裁、副总裁、财务负责人和董事会秘书。 第四条 总裁及其他高级管理人员每届任期三年，期限届满后连聘可以连任。 第五条 总裁及其他高级管理人员可以在任期届满以前提出辞职。 第三章 总裁办公会议制度 第六条 公司实行总裁负责下的总裁办公会 ...

山东金城医药集团股份有限公司 投资者关系管理制度 山东金城医药集团股份有限公司 第一条 为规范公司投资者关系管理工作，加强公司与投资者之间的有效沟通，促 进公司完善治理，提高公司质量，切实保护投资者特别是中小投资者合法权益，根据《中 华人民共和国公司法》《上市公司治理准则》《上市公司与投资者关系管理工作指引》 《深圳证券交易所创业板股票上市规则》《深圳证券交易所上市公司自律监管指引第 2 号—创业板上市公司规范运作》等相关法律、行政法规、规范性文件及《山东金城医药 集团股份有限公司章程》（以下简称"《公司章程》"）的规定，结合本公司实际情况， 制定本制度。 投资者关系管理制度 第一章 总则 （二）平等性原则：公司开展投资者关系管理活动，应当平等对待所有投资者，尤 第二条 投资者关系管理是指公司通过便利股东权利行使、信息披露、互动交流和 诉求处理等工作，加强与投资者之间的沟通，增进投资者对公司的了解和认同，提高 公司治理水平和企业整体价值，实现尊重投资者、回报投资者、保护投资者目的的相 关活动。 第三条 投资者关系管理的目的： （一）促进公司与投资者之间的良性关系，增进投资者对公司的了解，通过充分的 信息披露加 ...